CUREVAC NV (CVAC) Stock Fundamental Analysis

NASDAQ:CVAC • NL0015436031

4.66 USD
-0.01 (-0.21%)
At close: Jan 5, 2026
4.62 USD
-0.04 (-0.86%)
After Hours: 1/5/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, CVAC scores 3 out of 10 in our fundamental rating. CVAC was compared to 521 industry peers in the Biotechnology industry. CVAC has an average financial health and profitability rating. CVAC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • CVAC had negative earnings in the past year.
  • In the past year CVAC has reported a negative cash flow from operations.
  • In the past 5 years CVAC reported 4 times negative net income.
  • In multiple years CVAC reported negative operating cash flow during the last 5 years.
CVAC Yearly Net Income VS EBIT VS OCF VS FCFCVAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M -800M

1.2 Ratios

  • CVAC's Return On Assets of 11.31% is amongst the best of the industry. CVAC outperforms 93.77% of its industry peers.
  • CVAC has a better Return On Equity (14.79%) than 94.53% of its industry peers.
  • CVAC has a better Return On Invested Capital (14.12%) than 95.47% of its industry peers.
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROIC 14.12%
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
CVAC Yearly ROA, ROE, ROICCVAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • CVAC has a Profit Margin of 182.11%. This is amongst the best in the industry. CVAC outperforms 98.49% of its industry peers.
  • CVAC has a Operating Margin of 212.01%. This is amongst the best in the industry. CVAC outperforms 100.00% of its industry peers.
  • Looking at the Gross Margin, with a value of 93.01%, CVAC belongs to the top of the industry, outperforming 93.40% of the companies in the same industry.
Industry RankSector Rank
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVAC Yearly Profit, Operating, Gross MarginsCVAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CVAC is creating value.
  • CVAC has about the same amout of shares outstanding than it did 1 year ago.
  • CVAC has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CVAC has been reduced compared to a year ago.
CVAC Yearly Shares OutstandingCVAC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CVAC Yearly Total Debt VS Total AssetsCVAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • CVAC has an Altman-Z score of 4.23. This indicates that CVAC is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.23, CVAC is in the better half of the industry, outperforming 71.70% of the companies in the same industry.
  • CVAC has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • CVAC has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: CVAC outperforms 42.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACC1.96
WACC7.21%
CVAC Yearly LT Debt VS Equity VS FCFCVAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

  • A Current Ratio of 3.70 indicates that CVAC has no problem at all paying its short term obligations.
  • The Current ratio of CVAC (3.70) is comparable to the rest of the industry.
  • CVAC has a Quick Ratio of 3.69. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CVAC (3.69) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.69
CVAC Yearly Current Assets VS Current LiabilitesCVAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for CVAC have decreased strongly by -247.92% in the last year.
  • CVAC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.98%.
  • The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%

3.2 Future

  • Based on estimates for the next years, CVAC will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
  • Based on estimates for the next years, CVAC will show a very negative growth in Revenue. The Revenue will decrease by -11.14% on average per year.
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CVAC Yearly Revenue VS EstimatesCVAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CVAC Yearly EPS VS EstimatesCVAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CVAC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVAC Price Earnings VS Forward Price EarningsCVAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • CVAC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CVAC is cheaper than 99.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.08
CVAC Per share dataCVAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • CVAC's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CVAC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CUREVAC NV

NASDAQ:CVAC (1/5/2026, 8:00:00 PM)

After market: 4.62 -0.04 (-0.86%)

4.66

-0.01 (-0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)04-08
Inst Owners10.45%
Inst Owner Change-75.52%
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap1.05B
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target5.57 (19.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)1.84%
Min EPS beat(4)-39.67%
Max EPS beat(4)35.41%
EPS beat(8)3
Avg EPS beat(8)1.3%
EPS beat(12)5
Avg EPS beat(12)-6.32%
EPS beat(16)8
Avg EPS beat(16)6.13%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)16.57%
PT rev (3m)13.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)0%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.77
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.07
EV/EBITDA 3.08
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.36
BVpS4.49
TBVpS4.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROCE 16.62%
ROIC 14.12%
ROICexc 26.37%
ROICexgc 27.79%
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
FCFM N/A
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.18
Cap/Depr 28.09%
Cap/Sales 7.01%
Interest Coverage 66.45
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.69
Altman-Z 4.23
F-Score3
WACC7.21%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A

CUREVAC NV / CVAC FAQ

Can you provide the ChartMill fundamental rating for CUREVAC NV?

ChartMill assigns a fundamental rating of 4 / 10 to CVAC.


Can you provide the valuation status for CUREVAC NV?

ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (CVAC). This can be considered as Overvalued.


How profitable is CUREVAC NV (CVAC) stock?

CUREVAC NV (CVAC) has a profitability rating of 5 / 10.


What is the financial health of CUREVAC NV (CVAC) stock?

The financial health rating of CUREVAC NV (CVAC) is 5 / 10.


What is the expected EPS growth for CUREVAC NV (CVAC) stock?

The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -163.99% in the next year.